{"id":666208,"date":"2010-02-16T09:54:49","date_gmt":"2010-02-16T14:54:49","guid":{"rendered":""},"modified":"2026-10-04T10:38:24","modified_gmt":"2026-10-04T14:38:24","slug":"first-in-class-hcv-drug-licensed-by-novartis","status":"publish","type":"post","link":"https:\/\/mereja.com\/index\/666208","title":{"rendered":"First-in-Class HCV Drug Licensed by Novartis"},"content":{"rendered":"<p>Novartis licenses alisporivir, a new drug that is currently in Phase IIb development for the treatment of Hepatitis C.<\/p>\n<p>Novartis licenses Hepatitis C drug<\/p>\n<p>Feb. 9, 2010<\/p>\n<p>By Steve Goldstein<\/p>\n<p>LONDON (MarketWatch) &#8212; Novartis \/quotes\/comstock\/13*!nvs\/quotes\/nls\/nvs (NVS 53.73, +0.02, +0.04%) \/quotes\/comstock\/06p!novn (CH:NOVN 57.80, 0.00, 0.00%) said it has licensed Debio 025, or alisporivir, a potential first-in-class antiviral agent currently in Phase IIb development for the treatment of hepatitis C. Debio 025 is the first in a new class of drugs called cyclophilin inhibitors which could become part of the future standard of care for the disease.<\/p>\n<p>Continue reading this entire article:<br \/>\n<a href=\"http:\/\/www.marketwatch.com\/story\/novartis-licenses-hepatitis-c-drug-2010-02-09\">http:\/\/www.marketwatch.com\/story\/novartis-licenses-hepatitis-c-drug-2010-02-09<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novartis licenses alisporivir, a new drug that is currently in Phase IIb development for the treatment of Hepatitis C. Novartis licenses Hepatitis C drug Feb. 9, 2010 By Steve Goldstein LONDON (MarketWatch) &#8212; Novartis \/quotes\/comstock\/13*!nvs\/quotes\/nls\/nvs (NVS 53.73, +0.02, +0.04%) \/quotes\/comstock\/06p!novn (CH:NOVN 57.80, 0.00, 0.00%) said it has licensed Debio 025, or alisporivir, a potential first-in-class [&hellip;]<\/p>\n","protected":false},"author":288,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"advanced_seo_description":"","jetpack_seo_html_title":"","jetpack_seo_noindex":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[4821],"tags":[],"class_list":["post-666208","post","type-post","status-publish","format-standard","hentry","category-news"],"jetpack_featured_media_url":"","jetpack_shortlink":"https:\/\/wp.me\/p9NivD-2Nji","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/posts\/666208","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/users\/288"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/comments?post=666208"}],"version-history":[{"count":1,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/posts\/666208\/revisions"}],"predecessor-version":[{"id":767249,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/posts\/666208\/revisions\/767249"}],"wp:attachment":[{"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/media?parent=666208"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/categories?post=666208"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/tags?post=666208"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}